Grünenthal, Patheon Partner for Abuse-Deterrent Formulations
By

Patheon has signed a strategic agreement with Grünenthal, an independent, family-owned, research-based pharmaceutical group headquartered in Aachen, Germany to serve as its preferred development partner for its products made using Grünenthal's abuse-deterrent formulation technology INTAC, the company’s technology designed to reduce the potential for abuse of controlled substances.

Patheon was selected to assist with the development of advanced INTAC-based products, including single-entity and fixed-dose combination solid oral dosage forms with immediate- and modified-release properties.

As part of the agreement, Grünenthal has agreed to install specialized equipment in Patheon's Cincinnati manufacturing site. Through their partnership, Grünenthal and Patheon will partner to offer new solutions to the broader pharmaceutical industry.

Source: Grünenthal

Leave a Reply

Your email address will not be published. Required fields are marked *